AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34322775
Drug: Copanlisib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib (45 mg and 30 mg intravenously on days 1, 8, and 15 of 28-day cycles) in combination with cetuximab (standard doses of 400 mg/m weekly)
Trial: 34323413
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of collagenase Clostridium histolyticum (CCH) at high doses (0.1-0.2 mg/cm)
Trial: 34323413
Drug: Verteporfin and
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin and nintedanib (FDA-approved drugs)
Trial: 34323955
Drug: Weekly isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly isoniazid and rifapentine (3HP) at standard doses (900 mg/week)
Trial: 34323955
Drug: Weekly isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly isoniazid and rifapentine (3HP) in pregnant women with HIV
Trial: 34323955
Drug: Weekly isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly isoniazid and rifapentine (3HP)
Trial: 34323958
Drug: G-CHOP (Obinutuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CHOP (Obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Trial: 34324028
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 mg single dose
Trial: 34324028
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg daily (MHI)
Trial: 34324028
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg or 300 mg based on weight and platelets (NHF)
Trial: 34324392
Drug: Anti-CD7 CAR
RxNorm normalized name: Anti-CD7 CAR T-cell therapy
DrugBank: Anti-CD7 CAR T-cell therapy (DB18128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD7 CAR T cells, single infusion at a dose of 5 × 10
Trial: 34324451
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) initiated in the first week of life
Trial: 34325107
Drug: Neoadjuvant or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant or conversion chemotherapy
Trial: 34326007
Drug: Phosphodiesterase type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase type 5 inhibitors (PDE5Is)
Trial: 34327136
Drug: Penpulimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penpulimab (200 mg i.v. Q3W) plus Anlotinib (8 mg/day, 2 weeks on/1 week off)
Trial: 34327344
Drug: Iguratimod (IGU)
RxNorm normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Iguratimod (IGU) 25 mg bid as monotherapy or to background therapy
Trial: 34327344
Drug: Iguratimod (IGU)
RxNorm normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Iguratimod (IGU) 25 mg bid
Trial: 34327406
Drug: Detachable string
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detachable string magnetically controlled capsule endoscopy (DS-MCCE)
Trial: 34327510
Drug: Nonablative, Noncoagulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonablative, Noncoagulative Multipolar Radiofrequency and Pulsed Electromagnetic Field Treatment
Trial: 34327561
Drug: dd-ABVD (dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dd-ABVD (dose-dense ABVD)
Trial: 34327604
Drug: Standardized Aronia
RxNorm normalized name: Aronia melanocarpa fruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Aronia melanocarpa extract (SAE) 30 ml/day for 30 days
Trial: 34329576
Drug: Venetoclax added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax added to CLIA (cladribine, high-dose cytarabine, idarubicin)
Trial: 34329772
Drug: PRESERFLO® MicroShunt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2-0.4 mg/ml) for 2-3 minutes
Trial: 34329772
Drug: PRESERFLO® MicroShunt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2 mg/ml)
Trial: 34329772
Drug: PRESERFLO® MicroShunt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.4 mg/ml)
Trial: 34329846
Drug: Budigalimab 375
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab 375 mg via intravenous infusion every 3 weeks plus Rova-T 0.3 mg/kg intravenously on day 1 of the first and third 3-week cycle
Trial: 34329939
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg b.i.d. + intravenous pegylated liposomal doxorubicin (PLD) 40 mg/m²
Trial: 34329939
Drug: PLD 30
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 30 mg/m²
Trial: 34330322
Drug: Paquinimod 3
RxNorm normalized name: Paquinimod
DrugBank: Paquinimod (DB13118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paquinimod 3 mg/day for 8 weeks
Trial: 34330671
Drug: Radiofrequency (RF)
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency (RF) applications targeting the atrial edge of the leak, average 18 ± 7 RF applications per patient, mean maximum contact force 16 ± 3 g, mean power 44 ± 2 W, mean RF time 5.1 ± 2.5 minutes.
Trial: 34330715
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection after neoadjuvant treatment
Trial: 34330766
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (TVEC) with concurrent preoperative external beam radiation therapy (EBRT)
Trial: 34330842
Drug: ASTX029, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX029, a dual-mechanism ERK inhibitor
Trial: 34330906
Drug: ChAdOx1 Chik
RxNorm normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 Chik vaccine (single intramuscular injection at one of three preestablished dosages)
Trial: 34330906
Drug: ChAdOx1 Chik
RxNorm normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 Chik vaccine (single intramuscular injection)
Trial: 34330906
Drug: ChAdOx1 Chik
RxNorm normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 Chik vaccine
Trial: 34330970
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug (NSAID) intake
Trial: 34331051
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine in ARD group
Trial: 34331111
Drug: Bortezomib in
RxNorm normalized name: bortezomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib in combination with fludarabine plus cyclophosphamide (B-FC)
Trial: 34331589
Drug: Anamorelin 100
RxNorm normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anamorelin 100 mg orally daily with standardized physical activity and nutrition counseling for 43 days
Trial: 34332992
Drug: Cap-based adjuvant
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap-based adjuvant chemotherapy
Trial: 34333554
Drug: Lutetium-177 treatment
RxNorm normalized name: Lutetium-177
DrugBank: Lutetium Lu-177 (DB13982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutetium-177 treatment
Trial: 34334250
Drug: p75 neurotrophin
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p75 neurotrophin receptor intervention
Trial: 34334342
Drug: InterStim implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InterStim implant (de novo group)
Trial: 34334342
Drug: InterStim implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InterStim implant (replacement group)
Trial: 34334342
Drug: InterStim implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InterStim implant
Trial: 34334713
Drug: Intravenous ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous ustekinumab
Trial: 34335336
Drug: Web-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based intervention to promote positive mental health, details on dosage and duration not available.
Trial: 34335465
Drug: Low-dose relacorilant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose relacorilant (100-200 mg/d) for 12 weeks
Trial: 34335465
Drug: High-dose relacorilant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose relacorilant (250-400 mg/d) for 16 weeks
Trial: 34335479
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning clustering based on AUCs of glucose and insulin during OGTT, and uric acid.
Trial: 34336760
Drug: Patient-centered care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered care and gentle approach to treatment
Trial: 34339017
Drug: Proactive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive management (PM) using calcipotriene 0.005%/betamethasone dipropionate 0.064% foam, twice-weekly during maintenance phase
Trial: 34341142
Drug: anti-CD20 therapies
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD20 therapies
Trial: 34341335
Drug: AZD1222 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1222 vaccine (one dose)
Trial: 34341335
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with anti-CD38 monoclonal antibodies or belantamab mafodotin
Trial: 34342593
Drug: Telehealth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth intervention focusing on hypoglycemia education and symptom monitoring, including initial in-person visit, 3 weekly telecoaching calls, 1 biweekly call, and final in-person visit over 8 weeks.
Trial: 34343354
Drug: Tafasitamab 12
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tafasitamab 12 mg/kg weekly for up to four 28-day cycles
Trial: 34344873
Drug: Radiolabeled epichaperome
RxNorm normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabeled epichaperome probe administered by intravenous injection (single microdose)
Trial: 34346900
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy delivered via a smartphone mHealth app
Trial: 34348724
Drug: Anticoagulant, antiaggregant,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant, antiaggregant, and anticoagulant plus antiaggregant drugs
Trial: 34348889
Drug: electronically delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: electronically delivered cognitive behavioral therapy (e-CBT) for OCD, 16-week program
Trial: 34348918
Drug: Manufacturer's recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufacturer's recommended threshold of 6 WHO U/mL
Trial: 34348942
Drug: Stepwise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise treatment algorithm based on BFI score
Trial: 34348942
Drug: Conventional laxatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional laxatives
Trial: 34348942
Drug: Peripherally acting
RxNorm normalized name: Peripherally acting antiobesity products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripherally acting mu-opioid receptor antagonist (PAMORA)
Trial: 34348942
Drug: PAMORA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAMORA and conventional laxative
Trial: 34348950
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy (MT) delivered in 10 sessions over 6 weeks with an accompanying home exercise programme (HEP)
Trial: 34349026
Drug: CPL207280, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPL207280, a GPR40/FFA1 agonist; specific dosage and duration not mentioned
Trial: 34349716
Drug: Arm Ergometry
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm Ergometry intervention, details on dosage and duration not available
Trial: 34352165
Drug: Second-Generation Antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-Generation Antipsychotics
Trial: 34352935
Drug: Poloxamer-based thermosensitive
RxNorm normalized name: Poloxamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poloxamer-based thermosensitive sol-gel (PTAS) agent applied to the operative field after ALND
Trial: 34353808
Drug: Cloxacillin 2
RxNorm normalized name: cloxacillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous for 7 days
Trial: 34353808
Drug: Cloxacillin 2
RxNorm normalized name: cloxacillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin 2 g/4-hour intravenous alone for 7 days
Trial: 34354225
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks for two cycles
Trial: 34354225
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks
Trial: 38062808
Drug: CAR T-cell
RxNorm normalized name: CD123-CD33cCAR T-cells
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR T-cell therapy
Trial: 34355155
Drug: 16 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g/day of inulin (prebiotic) supplementation
Trial: 34355741
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of gene alterations, number of metastatic sites, prior systemic therapies, presence of CTCs and PD-L1(+) CTCs
Trial: 34355741
Drug: Squamous cell
RxNorm normalized name: Vespula squamosa venom protein
DrugBank: Vespula squamosa venom protein (DB11032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squamous cell carcinoma histology, number of prior systemic treatments, presence of CTC
Trial: 34357561
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (once-daily)
Trial: 34358484
Drug: Infigratinib 125
RxNorm normalized name: INFIGRATINIB 125 mg ORAL CAPSULE [TRUSELTIQ]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infigratinib 125 mg orally once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death.
Trial: 34359048
Drug: SIACI of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIACI of bevacizumab (15 mg/kg) and cetuximab (200 mg/m2)
Trial: 34360156
Drug: COVID-19 vaccines
RxNorm normalized name: Covid-19 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccines (including booster doses)
Trial: 34361902
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements and exercise training
Trial: 34362494
Drug: C-CAR011 infusion
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-CAR011 infusion following lympho-depletion
Trial: 34362494
Drug: C-CAR011 infusion
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-CAR011 infusion
Trial: 34363393
Drug: Daily interactions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interactions
Trial: 34363598
Drug: Current therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapy and clinical practices for PDN
Trial: 34363598
Drug: Opium therapies
RxNorm normalized name: Opium
DrugBank: Opium (DB11130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opium therapies
Trial: 34363598
Drug: Contradiction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contradiction of second-line guideline recommendation for opium dosage form
Trial: 34363769
Drug: Parenteral low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral low-molecular-weight or unfractionated heparin for 72 hours followed by oral dabigatran 150 mg twice per day
Trial: 34365644
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg (twice daily)
Trial: 34365878
Drug: KA2237, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KA2237, a dual p110β/p110δ inhibitor, administered orally.
Trial: 34366928
Drug: CNS stimulants
RxNorm normalized name: CNS STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS stimulants (predominantly OROS-Methylphenidate, up to 54 mg per day)
Trial: 34367149
Drug: Haploidentical stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haploidentical stem cell transplantation (haplo SCT) and dinutuximab (anti-GD2 antibody)
Trial: 34367680
Drug: Canakinumab treatment
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab treatment for cytokine release syndrome (CRS) in COVID-19-induced pneumonia
Trial: 34367728
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2)
Trial: 34368242
Drug: Cardiac Shock
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Shock Wave Therapy
Trial: 34369187
Drug: Inflammation defined
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflammation defined by hs-CRP level of ≥1.0 mg/L
Trial: 34369333
Drug: CON (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (25 g whey protein hydrolysate)
Trial: 34369333
Drug: LOW (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW (25 g whey protein hydrolysate + 3179 mg Capolac®)
Trial: 34369333
Drug: MED (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MED (25 g whey protein hydrolysate + 6363 mg Capolac®)
Trial: 34369333
Drug: HIGH (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH (25 g whey protein hydrolysate + 9547 mg Capolac®)
Trial: 34369416
Drug: Cochlear implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implants (PTA ≥ 70 dB HL)
Trial: 34369424
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate (MPA) 150-mg intramuscular injection
Trial: 34369424
Drug: Efavirenz-based HIV
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based HIV therapy and rifampicin plus isoniazid
Trial: 34369424
Drug: Depot MPA
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot MPA dosing frequency
Trial: 34370076
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg BID with rosuvastatin 20 mg
Trial: 34370076
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg BID with oral contraceptives
Trial: 34370076
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol 30 µg + levonorgestrel 150 µg)
Trial: 34370839
Drug: Anticancer drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticancer drugs (40 drugs significantly associated with diLQT)
Trial: 34370839
Drug: Anticancer drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticancer drugs (9 drugs associated with VA without diLQT)
Trial: 34370839
Drug: Kinase inhibitors
RxNorm normalized name: PROTEIN KINASE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinase inhibitors (20/49 drugs)
Trial: 34370839
Drug: Hormonal therapies
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapies (4/49 drugs)